M. Biakhov

1.2k total citations · 1 hit paper
19 papers, 899 citations indexed

About

M. Biakhov is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M. Biakhov has authored 19 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in M. Biakhov's work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). M. Biakhov is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). M. Biakhov collaborates with scholars based in Russia, United States and Germany. M. Biakhov's co-authors include Semiglazov Vf, José Baselga, David Dodwell, Anton Roth, Xiangyang Liu, Marek Pawlicki, Tadeusz Pieńkowski, Konstantinas Povilas Valuckas, Els Vercammen and George Manikhas and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M. Biakhov

19 papers receiving 871 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

2005 505 citations Brian Leyland‐Jones, Semiglazov Vf et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by M. Biakhov

Since Specialization

Citations

This map shows the geographic impact of M. Biakhov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Biakhov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Biakhov more than expected).

Fields of papers citing papers by M. Biakhov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Biakhov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Biakhov. The network helps show where M. Biakhov may publish in the future.

Co-authorship network of co-authors of M. Biakhov

This figure shows the co-authorship network connecting the top 25 collaborators of M. Biakhov. A scholar is included among the top collaborators of M. Biakhov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Biakhov. M. Biakhov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC). 2013 ·Journal of Clinical Oncology ·Lorena de la Peña, Javier Cortés, Alexey Manikhas, Laslo Roman, Semiglazov Vf, M. Biakhov, Lokanatha Dasappa, Antonio Llombart‐Cussac, Marcel Rozencweig, Salvatore Forenza, Ronald H. Goldfarb, Jeri Matera, N. Azarnia, Clifford A. Hudis, José Baselga	3
2	Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). 2013 ·Journal of Clinical Oncology ·Malcolm J. Moore, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Jeremy K. Hon, M. Biakhov, Sunil R. Hingorani, Vinod Ganju, Colin D. Weekes, Werner Scheithauer, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Xinyu Wei, Alfredo Romano	3
3	Phase II trial of huKS-IL2 with cyclophosphamide (CTX) in patients with extensive disease small-cell lung cancer (ED-SCLC). 2012 ·Journal of Clinical Oncology ·Oleg Gladkov, M. Biakhov, Rodryg Ramlau, Piotr Serwatowski, Janusz Milanowski, (unknown), Philip Komarnitsky, (unknown), Daniel Kramer, Maciej Krzakowski	4
4	Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis. 2011 ·Journal of Clinical Oncology ·Giampaolo Bianchini, Aleix Prat, Marlene Pickl, Anton Belousov, Astrid Koehler, Semiglazov Vf, W. Eiermann, S. Tjulandin, M. Biakhov, Aňa Lluch, Milvia Zambetti, (unknown), José Baselga, Lorenzo Gianni	16
5	PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. 2011 ·Journal of Clinical Oncology ·P. Gómez Pardo, Aleix Prat, Giampaolo Bianchini, Marlene Pickl, Anton Belousov, Astrid Koehler, Semiglazov Vf, W. Eiermann, S. Tjulandin, M. Biakhov, Aňa Lluch, Milvia Zambetti, (unknown), Lorenzo Gianni, José Baselga	6
6	nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study 2010 ·Expert Opinion on Drug Safety ·M. Biakhov, (unknown), José Iglesias, Neil Desai, Paul Bhar, Anita N. Schmid, Sibylle Loibl	14
7	Influence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): Results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone. 2010 ·Journal of Clinical Oncology ·Beihua Kong, M. Biakhov, Joseph L. Kelley, (unknown), Claudia Lebedinsky, Trilok Parekh, J. B. Vermorken	3
8	Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC) 2009 ·Journal of Clinical Oncology ·Robert H. Earhart, Sergey Cheporov, Oleg Gladkov, M. Biakhov, Hazel B. Breitz, Robert De Jager	4
9	210 POSTER Preliminary results of a Phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing first-line therapy for colorectal cancer (CRC) 2008 ·European Journal of Cancer Supplements ·Robert H. Earhart, Sergey Cheporov, Oleg Gladkov, M. Biakhov, Gizelle Baker, Hazel B. Breitz	1
10	First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC) 2008 ·Journal of Clinical Oncology ·David A. Karlin, Sergey Cheporov, Oleg Gladkov, M. Biakhov, Gizelle Baker, Hazel B. Breitz	3
11	A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer 2007 ·Breast Cancer Research and Treatment ·August Garin, Alexey Manikhas, M. Biakhov, (unknown), (unknown), Kurt Krejcy, (unknown), S. Tjulandin	24
12	A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer 2007 ·Oncology ·Craig Underhill, David Goldstein, Vera Gorbounova, M. Biakhov, I. Bazin, (unknown), Anwar M. Hossain, J. Blatter, Christopher Kaiser, Doreen Ma	16
13	Phase 1 study of picoplatin (pico) in combination with 5-fluorouracil (FU) and leucovorin (LV) as initial therapy in subjects with metastatic colorectal cancer (CRC) 2007 ·Journal of Clinical Oncology ·Oleg Gladkov, George Manikhas, M. Biakhov, S. Tjulandin, David A. Karlin	3
14	Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial 2005 ·Annals of Oncology ·Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning, M. Biakhov, David Irwin, Norbert Marschner, C. Slabber, George Fountzilas, A. Garin, (unknown), (unknown), G. Steger, T Südhoff, C. Giorgetti, Peter Reichardt	159
15	Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study breakdown → 2005 ·Journal of Clinical Oncology ·Brian Leyland‐Jones, Semiglazov Vf, Marek Pawlicki, Tadeusz Pieńkowski, Sergei Tjulandin, George Manikhas, (unknown), Anton Roth, David Dodwell, José Baselga, M. Biakhov, Konstantinas Povilas Valuckas, Э К Возный, Xiangyang Liu, Els Vercammen	505
16	A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): Preliminary results 2005 ·Journal of Clinical Oncology ·(unknown), Alexey Manikhas, M. Biakhov, (unknown), (unknown), Kurt Krejcy, (unknown), (unknown)	3
17	Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study 2004 ·Annals of Oncology ·Carmelo Pozzo, C. Barone, J. Szántó, (unknown), Christian Peschel, Johannes Bükki, В. А. Горбунова, Vahur Valvere, J. Załuski, M. Biakhov, Emmanuel Zuber, Christian Jacques, R. Bugat	126
18	Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study 2004 ·Cancer Cell International ·Pauline Wimberger, Alexander Burges, V. Gorbounova, H. Sommer, Barbara Schmalfeldt, Jacobus Pfisterer, M. Lichinitser, Anatoly Makhson, (unknown), W. Eiermann, M. Biakhov, (unknown), Andreas du Bois, Rainer Kimmig	1
19	Preliminary data of a phase II randomized trial of taxotere (TXT) and doxorubicin (DOX) given simultaneously or sequentially as 1st line chemotherapy (CT) for metastatic breast cancer (MBC) 1999 ·European Journal of Cancer ·И. А. Королева, Marek Z. Wojtukiewicz, J. Załuski, (unknown), M. Biakhov, (unknown), (unknown), (unknown), Clémence Dubois, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact